Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib, Steroids and Lenalidomide in RRMM
NCT03110822Phase 1Recruiting
- Sponsor
- ONCOtherapeutics
- Start
- Feb 2017
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ruxolitinib in multiple myeloma (MM), sponsored by ONCOtherapeutics. Primary endpoints: Maximum Tolerated Dose at 30 months and Treatment-Emergent Adverse Events at 54 months. Started Feb 2017; status: recruiting.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03110822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110822.